Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

and regulatory processes related to carfilzomib, and potential benefits of the modification of the FOCUS Phase 3 study.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to:  Onyx may never receive marketing approval for carfilzomib; failures or delays in Onyx's clinical trials;  if approved, Onyx may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib; serious adverse side effects, if they are associated with carfilzomib; competition; government regulation; and  protection of Onyx's intellectual property.  Any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.  

(i)National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures

(ii)International Agency for Research on Cancer, GLOBOCAN 2002 database


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Executive Officer of Regulus, will present a company overview ... Healthcare Conference on Wednesday, March 4, 2015 at 9:20 ... Boston Marriott Copley Place.  The presentation ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... (OTC Bulletin Board: WGBS), a leading developer of ... research systems,today announced that Kumar Kastury, Ph.D., vice ... on its SmartChip(TM),Real-Time PCR System at the Cambridge ... will be held June 8-11, 2008, at,the Fairmont ...
... OncoGenex Technologies Inc. will,present at the Needham & ... June 11 at 3 p.m. ET at the ... Officer, Scott Cormack, will,provide a corporate overview at ... recent data presentations from the American Society of,Clinical ...
... Powerful New Tool for Early Identification of High Risk ... Intervention Can Help Prevent Disease Progression, ... announced,today at the 68th Scientific Sessions of the American ... its novel PreDx(TM) Diabetes,Risk Test, a first-of-its-kind predictive tool ...
Cached Biology Technology:WaferGen to Present at the Ninth Annual Beyond Genome Conference 2OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference 2OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference 3Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 2Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 3Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 4
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
(Date:2/5/2015)... N.C. , Feb. 5, 2015  Marken is ... logistics company and has launched a new marketing campaign ... Logistics Organization (CLO).  The new campaign focuses on ... patient, protocol and shipments. The first headline ... , aligns Marken,s priorities with its client,s priorities. Marken ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-06/sfeb-apr062110.php,">Chinese . ... progressive disease, marked by shortness of breath and ... Increased pressure in the pulmonary artery and its ... endothelial and smooth muscle cells leading to excessive ...
... 2010)The nations of East and Central Africa have ... of humankind,s closest relativesthe eastern chimpanzeefrom hunting, habitat ... announcement made today by the Wildlife Conservation Society ... Nature (IUCN). The ambitious plantitled "Eastern ...
... National Oceanography Centre and the University of Glasgow show ... dynamics of plankton patches in the upper ocean. ... numbers in the sunlit upper ocean. Through the process ... starting with just water and carbon dioxide, which is ...
Cached Biology News:A possible role for Smurf1 in pulmonary arterial hypertension 2African nations commit to saving chimps 2African nations commit to saving chimps 3Ocean stirring and plankton patchiness 2
Request Info...
Recombinant Rhesus Macaque IFN-alpha...
9 D10...
... 500 g protein ... mouse whole cell lysate; Abelson transformed ... provided as Western blotting positive control, ... freezing and thawing should be minimized, ...
Biology Products: